Boundless Bio
2 known investors
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical Devices
2 known investors
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.